Oleksandr Petrenko
banner
opetrenko.bsky.social
Oleksandr Petrenko
@opetrenko.bsky.social
🇺🇦 scientist-physician | Target Discovery | Chronic Liver Disease | Fibrosis | #SystemsBiology | #CompBio.
Researching as cell & computer wizard @ MedUni Vienna & CeMM.

orcid.org/0000-0002-8586-4910
One from @genomicsUA.bsky.social
New insights into alcohol-related liver disease: in the recent preprint, we mapped niche-specific cell interactions at ultra-high resolution (2μm spots), described hepatic niche markers, and cell subtypes defined by them. Stay tuned!
#ALD #SpatialBiology #Fibrosis 🧪

www.biorxiv.org/content/10.1...
March 21, 2025 at 8:26 PM
Apparently so!
The first two cases were documented there, a fascinating discovery.
March 5, 2025 at 6:39 PM
Can we please take a moment and congratulate my colleague
@georg-semmler.bsky.social with publication of his study on Tangier disease, an extremely rare disease caused by ABCA1 defect with no existing treatment?
Great journey with lipidomids & metabolomics of TD 🧪

academic.oup.com/jcem/advance...
March 5, 2025 at 10:27 AM
Recently, I had several conversations with my American friends regarding Trump's statements on #Ukraine and the "urgent need" for elections in Ukraine. Given that this topic is of high speculation currently, I am sharing a personal viewpoint from a recent reply:
March 4, 2025 at 6:54 AM
After years of confronting the russian propaganda narrative on "NATO-funded bioweapon research in Ukraine," I feel somewhat disappointed that it's not true. If it was, that would be a hell of a PhD project idea without even needing to leave my own country.
February 3, 2025 at 8:05 AM
/5 This project has been a rewarding ~four-year journey since the initial discussions with my colleagues Georg Semmler and Bernhard Scheiner. Thanks to the patients, clinical team, collaborators, and CeMM Molecular Discovery Platform for making this possible!

Img: graphical abstract.
September 5, 2024 at 12:19 PM
/4 Together with colleagues from the University of Barcelona Clinical Hospital, we showed the role of taurocholic acid or taurocholic/L-aspartic acid ratio in distinguishing PSVD from healthy and cirrhosis profiles accordingly (AUROC = 0.9 / 0.72) in validation.

Img: Fig. 5E
September 5, 2024 at 12:18 PM
3/ We used machine learning models that distinguished PSVD from healthy individuals using a six-metabolite panel (sensitivity 0.95, specificity 1), and from cirrhosis with four metabolites (0.8 & 0.9). Adipic acid was in both.

Img: Fig. 4 (license: CC BY-NC-ND 4.0 & further)
September 5, 2024 at 12:17 PM
1/ 🧪🧵Porto-sinusoidal vascular disorder (#PSVD) is a rare condition. Despite its known hallmarks, much remains unclear, including its pathobiology and the potential for non-invasive testing.

Our new paper explores PSVD from a metabolomics angle:
jhep-reports.eu/article/S258...
September 5, 2024 at 12:15 PM